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One of the challenges of tailored antiangiogenic therapy is the ability to adequately monitor the angiogenic activity
of a malignancy in response to treatment. The αvβ3 integrin, highly overexpressed on newly formed tumor vessels,
has been successfully used as a target for Arg-Gly-Asp (RGD)–functionalized nanoparticle contrast agents. In the
present study, an RGD-functionalized nanocarrier was used to image ongoing angiogenesis in two different xeno-
graft tumor models with varying intensities of angiogenesis (LS174T > EW7). To that end, iron oxide nanocrystals
were included in the core of the nanoparticles to provide contrast for T2*-weighted magnetic resonance imaging
(MRI), whereas the fluorophore Cy7 was attached to the surface to enable near-infrared fluorescence (NIRF)
imaging. The mouse tumor models were used to test the potential of the nanoparticle probe in combination with
dual modality imaging for in vivo detection of tumor angiogenesis. Pre-contrast and post-contrast images (4 hours)
were acquired at a 9.4-T MRI system and revealed significant differences in the nanoparticle accumulation patterns
between the two tumor models. In the case of the highly vascularized LS174T tumors, the accumulation was more
confined to the periphery of the tumors, where angiogenesis is predominantly occurring. NIRF imaging revealed
significant differences in accumulation kinetics between the models. In conclusion, this technology can serve as
an in vivo biomarker for antiangiogenesis treatment and angiogenesis phenotyping.
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Angiogenesis is one of the crucial processes in tumor growth and
development and is considered to predict short-term survival. Com-
pared to the highly organized morphology of blood vessels in healthy
tissues, the tumor vasculature is characterized by a chaotic architec-
ture, tortuous vessel structure, and a leaky endothelium [1]. While
many angiogenesis inhibitors are already known for decades [2], it
was not until 2004 that the Food and Drug Administration approved
the first antiangiogenic drug (bevacizumab) for clinical use [3,4].
Agents targeting different angiogenic pathways were subsequently
approved [5] or are currently in different stages of clinical trails
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inherent or acquired tumor resistance, increased tumor invasiveness,
limited effects on overall survival, and, notably, a lack of reliable and
thoroughly validated predictive biomarkers to monitor response to
treatment [6,7]. For the latter, imaging is being considered as an
approach to noninvasively track response to antiangiogenic therapy
[9]. The most common standardized ex vivo measure of angiogenesis
of tissue specimens is the determination of the microvessel density
(MVD). Quantification of the MVD is performed by counting the
(maximal) number of stained blood vessels per defined area on a
histologic section [10]. In vivo imaging readouts of MVD include
dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
[11], dynamic contrast-enhanced computed tomography [12], ultra-
sound [13], positron emission tomography [14], and optical methods
[15,16]. Among those, DCE-MRI is the most widely explored method
for monitoring response to antiangiogenic tumor therapy in both ani-
mal models [17] and clinical studies [18,19]. It relies on the fast acqui-
sition of T1-weightedMR images after rapid intravenous (i.v.) injection
of gadolinium-based contrast agents [20]. DCE-MRI was used in a
recent study to investigate its potential as a biomarker for the treatment
of metastatic renal cancer with the receptor tyrosine kinase inhibitor
sorafenib, which blocks the vascular endothelial growth factor receptor
[21]. Whereas DCE-MRI–derived parameters could be shown as phar-
macodynamic biomarkers for this agent, variability was high, and there-
fore further refinements of the data acquisition and analysis are needed.
Within the field of molecular imaging, nanotechnology, in particu-
lar, the development of nanoparticle contrast agents, has seen unprec-
edented growth in the last years [22]. Because of their ability to
incorporate high payloads of contrast agents/drugs as well as the possi-
bility to covalently attach targeting molecules to the surface [23], their
use to also investigate angiogenic processes has emerged as a very prom-
ising tool in cancer research [24,25]. The αvβ3 integrin is known to be
significantly upregulated on activated endothelial cells during neoangio-
genesis. By binding to the sequence arginine-glycine-aspartate (RGD),
it mediates its biologic activity, and therefore, this peptide sequence has
been used to functionalize contrast agents/nanoparticles for targeting
the tumor neovasculature [26–28].
In the current study, the RGD peptide was attached to the surface
of a nanoparticle platform that we described previously [29]. It is based
on oil-in-water nanoemulsions with a tunable particle size in a range of
30 to 100 nm and the possibility to include lipophilic contrast agents/
drugs in the core as well as amphiphilic ones in the corona.
Here, we focused on iron oxide–enhanced T2*-weighted MRI and
near-infrared fluorescence (NIRF) imaging (Cy7 fluorophore), two
very complementary imaging modalities of RGD-functionalized nano-
particles. The first modality was used to acquire spatial distribution of
angiogenic activity at a given time point, whereas NIRF imaging pro-
vided time-resolved information about the nanoparticle binding kinetics
in the tumors over a period of 24 hours. Two xenograft tumormodels—
the highly angiogenic human colorectal LS174T [30] model and the
slow growing and low vascular density human EW7 Ewing sarcoma
model [31]—were chosen to evaluate our approach with regard to its
capability to adequately distinguish different intensity levels of angio-
genesis. Moreover, the latter model is known to show abundant vascular
mimicry in the outer rim of the tumors, a phenomenon in which tumor
cells form tubular structures that contribute to circulation [32], explain-
ing the lower MVD. These fundamental differences between the EW7
and LS174T tumors made us decide that the EW7 group injected with
targeted contrast agent served as a control for the LS174T groupsexamined in this study. Confocal laser scanning microscopy (CLSM) and
histologic staining for iron oxide were used to examine the location of the
nanoparticles in the tumor tissues and corroborate the in vivo findings.
Materials and Methods
Materials
Distearoyl-sn-glycero-3-phosphocholine, distearoyl-phosphoethanolamine-
N -[methoxy(polyethylene glycol)-2000] ammonium salt (DSPE-PEG),
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N -[maleimide
(polyethylene glycol)-2000] ammonium salt [DSPE-PEG (maleimide)],
1,2-dimyristoyl-sn-glycero-3-phospho-ethanolamine-N -(lissamine
rhodamine B sulfonyl), and distearoyl-phosphoethanolamine-N -
[amino(polyethylene glycol)-2000] [DSPE-PEG (amino)] were all pur-
chased from Avanti Polar Lipids (Alabaster, AL). Oleic acid–coated
magnetite (Fe3O4) particles with an average diameter of 10 nm were
obtained as a powder from NN-Labs (Fayetteville, AR). The cyclic
5-mer RGD (c[RGDf(S-acetylthioacetyl]K) was obtained from Peptides
International (Louisville, KY). The Cy7 N-hydroxysuccinimide (NHS)
ester was purchased from Amersham Biosciences (Piscataway, NJ). Cell
culture supplies were purchased from Invitrogen (Carlsbad, CA).
Synthesis of the Nanoemulsions
For the synthesis of the nanoemulsions, separate stock solutions of
all the lipophilic components were prepared in chloroform. The
Cy7–DSPE-PEG lipid was synthesized using the DSPE-PEG (amino)
lipid and Cy7 NHS ester as described earlier [29]. The composition of
the formulation was 2.7 mg of distearoyl-sn-glycero-3-phosphocholine,
9.1 mg of DSPE-PEG, 38 mg of soybean oil, 19.8 mg of iron oxide
particles, 1.06 mg of DSPE-PEG (maleimide), 746 μg of Cy7–DSPE-
PEG lipids (= 0.22 μmol Cy7), and 40 μg of 1,2-dimyristoyl-sn-
glycero-3-phospho-ethanolamine-N -(lissamine rhodamine B sulfonyl).
The components were mixed together and the solvent was evaporated
in a rotary evaporator under maximum vacuum in a 70°C water bath.
The formed lipid layer was hydrated with 10 ml of Hepes-buffered
saline (2.38 g/l Hepes and 8 g/l NaCl, pH 6.7), and the crude emulsion
was homogenized by sonication using a sonicator tip (BioLogics, Inc.,
3.9mm).The formulationwas sonicated for 20minutes (level 20%, pulse
70%, device: Biologics, Inc., ultrasonic homogenizer model 150 V/T)
while being cooled with room temperature water. Finally, the nano-
particle suspension was concentrated to a final volume of 2 ml by using
a Vivaspin 6 centrifugal filter device (membrane cutoff: 100 kDa;
Sartorius Corporation, Edgewood, NY) and divided into two batches
of 1 ml each. Cyclic RGD was activated by adding 5 μl of deacetylation
solution (348 mg of hydroxylamine HCl, 1.19 g of Hepes, 98 mg of
EDTA in 10 ml of Millipore water; pH 7.0) to 50 μl of RGD stock
solution (2.5 mg/ml) and placed on a shaker at room temperature for
45 minutes. Twenty microliters of activated cyclic RGD solution was
added to one of the two batches of nanoemulsions for the coupling
reaction to take place overnight at 4°C, while the other served as a
control. Both formulations were washed the next day by using Vivaspin
6 columns. To ensure that the formulations of different batches had the
same iron oxide content, T1 values of every batch of nanoemulsion
were measured (diluted 1:10 with water, 60-MHz Bruker Minispec
device operating at 40°C; BrukerMedical GmbH, Ettlingen,Germany).
Dynamic Light Scattering
Hydrodynamic sizes of the nanoparticles were measured by using
dynamic light scattering (Brookhaven Instruments, Holtsville, NY)
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mulation was diluted in 1 ml of Millipore water for the measurement.Cell Culture and Tumor Model
Human EW7 (Ewing’s sarcoma, a kind gift of Dr. O. Delattre,
Paris, France) cancer cells were cultured in RPMI 1640 medium and
human LS174T (colon carcinoma) cells were cultured in Dulbecco’s
modified Eagle’s medium, both supplemented with 10% fetal calf
serum. The cells were grown in a 5%CO2, water-saturated atmosphere
at 37°C, and subculturing was performed once a week by 1:10 dilution
after trypsinization. All animal handling protocols and procedures were
approved by the Mount Sinai School of Medicine Institutional Animal
Care and Use Committee. Six-week-old male Swiss nude mice were
purchased from Taconic (Albany, NY). Subcutaneous tumors were
established by injecting 2 million cells of the same cancer type in the
lower left and right flanks of the mouse, respectively.Study Outline
Two complementary imaging methods [22], NIRF imaging and
MRI, were used to examine the potential of the targeted nanoparticles
to serve as a contrast agent for the phenotyping of tumors with different
levels of angiogenesis (Figure 1). To that end, three different mouse
groups (six mice per group) were established to determine the time-
resolved accumulation by NIRF imaging: (1) LS174T mice injected
with RGD-conjugated nanoparticles: LS174T RGD; (2) mice with
LS174T tumors injected with unconjugated nanoparticles: LS174T
control; and (3) EW7-bearing mice injected with RGD nanoparticles:
EW7 RGD. All the groups used for the NIRF imaging experiments
were injected with nanoparticles lacking iron oxide nanocrystals.
MRI was used to investigate the spatial distribution of the contrastFigure 1. Conceptual scheme of the study characterizing the differen
experiments (six mice per group, two tumors per mouse). Nanoparti
NIRF imaging were lacking it. LS174T RGD, mice bearing LS174T tum
LS174T tumors injected with unconjugated nanoparticles; EW7 RG
LS174T comp, mice with LS174T tumors that were injected twice f
with RGD nanoparticles lacking iron oxide and the second with RGD
RGD, mice bearing LS174T tumors injected with RGD nanoparticles (iro
for the competition experiment.agent within the tumors in dependence of the presence or absence of
the targeting molecule RGD on the surface of the particles. The follow-
ing five groups were used to acquire the MRI data: (4) LS174T RGD,
(5) LS174T control, (6) EW7 RGD, (7) LS174T(C) RGD, and (8)
LS174T comp. Groups 7 and 8 were chosen for the competition exper-
iment. Group 7 was similar to group 4 but injected with a different
batch of RGD-conjugated (iron oxide) nanoparticles and used as control
for group 8. In the latter group, mice received two injections: The first
injection consisted of RGD nanoparticles lacking iron oxide and the
second one was given 1.5 hours afterward and contained RGD nano-
particles carrying iron oxide (same batch as used in group 7). For the first
injection, twice asmany particles were administered than for the second.
The purpose of the MRI competition experiment was to demon-
strate that the previously acquired specific accumulation (signal loss)
pattern of the RGD-targeted particles in LS174T tumors (group 4)
was caused by binding to the αvβ3 integrins rather than nonspecific
accumulation. This was performed by monitoring changes in the sig-
nal attenuation pattern after saturating αvβ3 integrins by nonlabeled
nanoparticles in the tumors before injection of the targeted nano-
particles carrying the iron oxide label. To achieve saturation, we
chose the injection of the first dose of unlabeled nanoparticles to
be twice that of the labeled nanoparticles.Near-infrared Fluorescence Imaging and Data Analysis
NIRF imaging was performed with a custom-made imaging system
[33,34] using a 760-nm excitation filter, an 800-nm emission filter, and
an exposure time of 700 ms. The camera of the device was operated
with the LabView software (National Instruments, Austin, TX, [35]).
Swiss nude mice were anesthetized with a 4% isoflurane/oxygen
gas mixture (400 ml/min initial dose) and maintained by using 1.5%t mouse groups selected for the in vivo NIRF imaging and the MRI
cles used for the MRI contained iron oxide, whereas those for the
ors injected i.v. with RGD nanoparticles; LS174T control, mice with
D, mice bearing EW7 tumors injected with RGD nanoparticles;
or the competition experiment. The first injection was performed
nanoparticles carrying iron oxide 1.5 hours afterward; LS174T(C)
n oxide, same batch as used for LS174T comp) to serve as a control
Figure 2. T2*-weighted gradient echo pre-injection (A–D) and post-injection (E–H; 4 hours, 36.7 mg/kg Fe) MR images of subcutaneous
LS174T and EW7 tumors in Swiss nude mice (position unchanged in coil). The tumors of the LS174T RGD group, i.v. injected with RGD-
conjugated nanoparticles, show a hypointense signal distribution (owing to iron oxide accumulation) confined to the periphery of the
tumor (E). The other groups, injected either with the unconjugated particles (F), after a competition experiment (G), or in the case of the
other tumor model (EW7) characterized by a lower angiogenesis level (H), are rather marked by a homogenous pattern spread through-
out the entire tumor section. (TR = 120 ms, TE = 3 ms, 30° angle, Bruker 9.4 T).
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mice were injected i.v. with the nanoparticles through the tail vein. For
the time-resolved accumulation, imageswere acquired 5minutes, 15min-
utes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 24 hours after
i.v. injection. The mice were perfused with phosphate-buffered saline
containing 20 U heparin/ml directly afterward while being under iso-
flurane anesthesia. In three mice of each group, Alexa Fluor 488–
labeled isolectin GS-IB4 (a general stain for vascular endothelium;
Invitrogen) was administered i.v. 15 minutes before perfusion. Tumors
as well as organs were excised and imaged simultaneously with an
exposure time of 500 ms. Subsequently, the tumors were embedded
in Tissue-Tek (Sakura, Torrance, CA) and stored at −80°C.
For the data analysis of the fluorescence images (24-hour kinetics),
region-of-interests (ROIs) outlining the tumors as well as parts of the
skin, respectively, were drawn using ImageJ software. By using the fol-
lowing equation, the signal intensity of the tumor was normalized to
the signal intensity of the skin: NER = (I tumor − I skin)/I skin × 100%
(NER, normalized enhancement ratio; I tumor, signal intensity of tumor
ROI at certain time point; I skin, signal intensity of skin ROI at equal
time point). All calculated values were subtracted by the value deter-
mined at the 5-minute time point to correct for the blood pool signal.
To evaluate statistical significance, a two-way analysis of variance was
used and P values < .05 were considered as significant.
The biodistribution of the nanoparticles was evaluated by drawing
ROIs along the outlines of the excised tumors and organs. Subse-
quently, all relative fluorescence intensities I [I = (ROI area) × (mean
signal intensity of ROI)] corresponding to the different ROIs per
mouse were added up to create a 100% value (Io) to which all the
individuals values (I ) of the organs or tumors were normalized. The
determined values (I /Io) were averaged within the mouse groups
(Figure 6D). To assess the accumulation of the nanoparticles in the tu-
mors compared to the liver, the averaged tumor fluorescence intensities
were normalized to the liver intensity per mouse (I tumor/I liver × 100%)
and averaged again within the three different mouse groups.Immunohistochemistry, Confocal, and Perls Staining
To determine the MVD of the tumors, we cut 5-μm cryosections,
followed by fixation in acetone for 5 minutes at −20°C. After block-
ing unspecific sites by using 4% rabbit serum in phosphate-buffered
saline for 10 minutes, sections were incubated with rat anti-mouse
CD31 primary antibody (BD Pharmingen, Franklin Lakes, NJ) in
a dilution of 1:100 with 4% rabbit serum. A rabbit anti-rat second-
ary antibody and the alkaline phosphatase method served for the
staining (Vector ABC Kit; Vector Laboratories, Burlingame CA). Four
tumors of the EW7 RGD group and five tumors of the LS174T RGD
group were analyzed with one to two sections per tumor. Several digital
images of the tumor sections were photographed in bright field by using
the Axioplan 2IE microscope with a 20× objective and stitched together
by using the Axiovision 4.6.3 SP1 software to one image displaying the
entire tumor section. The CD31+ color (red) selection was performed
by using the gimp 2 software and converted to grayscale images. These
images showing only positive CD31 areas were inverted to white (signal)
on black (background) images. ROIs were drawn along the outlines of
the tumors and the area fraction in percent was determined by using
ImageJ software (Figure 8).MRI and Data Analysis
Nude mice bearing EW7 or LS174T subcutaneous tumors were
scanned under isoflurane anesthesia using a 9.4-T MRI system
(400.106 MHz; Bruker Instruments), operated by ParaVision soft-
ware 4.0. MRI was performed by using a gradient echo sequence
(T2*) with a repetition time (TR) of 120 ms, echo time (TE) of
3 ms, flip angle of 30°, field of view of 2.6 × 2.6 cm, matrix size of
128 × 128, 10 slices with a slice thickness of 1 mm, and 16 averages,
which amounted to a total scan time of 2.5 minutes. After the pre-
scans, mice were injected i.v. with the nanoemulsion (equivalent of
36.7 mg/kg iron oxide) and scanned up to 4 hours after injection in
30-minute steps, while the position of the mouse remained unchanged.
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made program written in MATLAB (MathWorks, Natick, MA). An
ROI was manually drawn along the outline of the selected tumor slice.
The program used this outer outline to automatically subdivide the
tumor section into five concentric sub-ROIs of equal area from the
periphery to the core (ROIs 1–5; Figure 3C ). For the pixel-by-pixel
analysis per ROI, a threshold of 4 × SD of the noise was set to define a
pixel of the 4-hour post-image to be “reduced” (hypointense because of
contrast agent accumulation) compared to the one of the pre-scanned
image. Two slices were analyzed per tumor, and the percentage of
reduced pixels per total number of pixels in the equal area ROI of
two slices was averaged in each mouse group and plotted against the
corresponding ROI. For the statistical analysis, a paired t test of the
values for the reduced pixels (%) of ROI 1 (periphery) versus ROI 5
(core) was performed for each mouse group. P values < .05 were con-
sidered as statistically significant.Results
In Vivo MRI
The distribution pattern of iron oxide nanoemulsions (mean par-
ticle size range, 75–85 nm) with and without the conjugation of
RGD in tumors was investigated by T2*-weighted MRI, which is
sensitive to the presence of iron. Five groups of mice were chosenFigure 3. For the evaluation of the MR images, the tumor area was div
post) per ROI was plotted against the corresponding ROI (A, B, D).
paring two different mouse groups injected just with different batche
ROI 1 and ROI 5). The two different tumor models injected with RGD
pixels per ROI from ROI 1 to ROI 5 (B) (**LS174T RGD: P = .008,
siderably different angiogenesis level. Whereas the competition group
shift of the entire pattern toward the one of the control can be observe
control: P > .05). Mean values ± SE.to compare the two different tumor models (LS174T vs EW7) with
distinct MVD and to perform a competition experiment (Figure 1;
for details, see Materials and Methods section). To minimize the error
for the pre-post quantification owing to movement or reposition of
the mouse after application of the contrast agent, we fixed and kept
the mice in the same position in the coil during the entire scan series.
In the pre-contrast images, the tumors appear isointense with their
surrounding muscle tissue (Figure 2, A–D). The mice were scanned
immediately after the administration of the nanoemulsion (equivalent
of 36.7 mg/kg iron oxide) and an intense homogeneous darkening of
the tumor area served as proof for a proper i.v. injection. On the basis
of the half-lives previously determined for the untargeted version of
the nanoemulsions [29], 4-hour post-administration was considered
to be sufficient for the necessary clearance of the particles from the
blood pool. Hypointense (dark) regions could be discerned within
the tumor area of the post-contrast images (4 hours) owing to the
accumulation of iron oxide. Importantly, the spatial distribution of
signal loss in the LS174T RGD group (Figure 2E ) differed from all
the other investigated groups (Figure 2, F–H ). While in the latter
groups the nanoparticles seemed to be distributed rather homoge-
nously, in the case of the LS174T tumors injected with the RGD-
functionalized nanoemulsions, the contrast agent was prevailingly
confined to the periphery of the tumors.
The statistical analysis of the acquired T2*-weighted tumor images
(for details, see Materials and Methods section) revealed a very highided into five ROIs (C) and the percentage of reduced pixels (pre vs
A very high grade of reproducibility could be achieved when com-
s of the same RGD-conjugated nanoparticles (A) (*P< .01 between
nanoemulsions show a very distinct rate of decrease in reduced
EW7 RGD: P = .88, LS174T control: P < .204), indicating a con-
LS174T compwas still significantly different between ROIs 1 and 5, a
d (D) (***LS174T(C) RGD: P < .05, LS174T comp: P < .05, LS174T
Figure 4. Fluorescence images (Cy7) of representatives of the two mouse groups injected with RGD-targeted nanoemulsions (LS174T
RGD: A–F, EW7 RGD: M–R) as well as of the group injected with untargeted nanoemulsions (LS174T control: G–L), showing the accumu-
lation of the contrast agent in subcutaneous tumor-bearing nude mice over a time period of 24 hours.
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the chart showing the percentage of reduced pixels per ROI plotted
against the corresponding ROI, two different groups of mice injected
with different batches of the RGD-conjugated contrast agent yielded
an almost identical signal loss pattern across the tumor (*P < .01 be-
tween ROI 1 and ROI 5). In comparison to the high statistically
significant difference of pixels with reduced intensity between the
tumor periphery and the core (P = .008) in the targeted LS174T
RGDmodel, the analysis of the EW7 RGD as well as the LS174T con-
trol group revealed no difference (EW7 RGD: P = .88, LS174T control:
P = .204; Figure 3B). The evaluation of the competition group that was
injected first with twice the amount of targeted nanoparticles lacking
iron oxide, followed by a second injection with targeted nanoparticles
carrying iron oxide, resulted in a distribution with a trend toward the
control (Figure 3D).Figure 5. Time-dependent tumor fluorescence signal of the three
mouse groups normalized to the skin and corrected for the blood
pool effect after injection. The analysis of the kinetics revealed a
statistically significant difference (P< .05) between the three groups
at the time points 1, 2, 4, and 6 hours after injection (LS174T RGD,
LS174T control: n = 12 tumors, EW7 RGD: n = 10 tumors, mean
values ± SE).In Vivo NIRF Imaging
Representative examples of mice for the different groups display
the results of the time-resolved accumulation of the nanoemulsions
in the tumors by using in vivo fluorescence imaging within a period
of 24 hours (Figure 4). The NER of the Cy7 fluorescence in percent
was plotted against time and revealed a statistically significant differ-
ence (P < .05) between all three investigated groups for the time
points 1, 2, 4, and 6 hours (Figure 5). The LS174T RGD group
was the one with the fastest accumulation kinetics. The analysis dem-
onstrated that the difference in tumor fluorescence intensity between
the two different cancer models was higher than the LS174T RGD
compared to the LS174 control for those time points. The mice were
sacrificed 24 hours after injection and perfused, and the organs aswell as tumors were imaged (Figure 6). The analysis of the fluo-
rescence intensities revealed a high-dose percentage of the contrast
agent in the tumors normalized to the liver for the LS174T RGD
mice (35%) compared to the EW7 RGD (17%) and the LS174T
control (19%; for details, see Materials and Methods section). The
result of the analysis of the organ fluorescence (I ) normalized to the
sum total of the fluorescence of the organs and the tumors (Io) is
depicted in Figure 6D.
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Perls staining was performed on fixed tumor sections to confirm
the presence of iron oxide delivered by the nanocarrier 24 hours after
i.v. administration. The results depicted in Figure 7, A–C , demon-
strate the association of the particles with tumor vessels in the example
of LS174T RGD, whereas, for the LS174T control tumors, the dis-
tribution was rather within the tissue (Figure 7D).
CLSM imaging corroborated the co-localization of the targeted nano-
particles (rhodamine B fluorescence) with microvessels (isolectin–Alexa
Fluor 488 stained; Figure 7, E–H), whereas control particles were again
spread within the tumor tissue (Figure 7, I–L).
The MVD of the two different tumor models was determined by
using CD31 staining. Tumor areas of one slide were photographed
sequentially with a system using a 20× objective and then auto-
stitched to display an entire section (CD31+: red; Figure 8A ). These
high-resolution images were transformed by using appropriate software
into a corresponding black and white image with white representing
positive CD31 signal (Figure 8B ). The result of the percentage area
analysis confirmed the statistically significant higher MVD of the
LS174T tumors compared to the EW7 (Figure 8C ).Discussion
In the present study, we demonstrated that our previously developed
nanoparticle platform can be functionalized with RGD to serve as a
contrast agent that allows the detection of ongoing angiogenesis and
the distinction between angiogenesis intensities of different tumorFigure 6. Fluorescence images (Cy7) of excised tumors and organs (
injection of the nanoparticles. The relative fluorescence counts of ea
including the two tumors per mouse and averaged for all the mice wit
EW7 RGD: n = 5 mice, mean value ± SD).models by two complementary and noninvasive imaging modalities,
i.e., MRI and NIRF. The combination of both modalities provided
spatiotemporal information about the accumulation and fate of the
probe. Analysis of the MR images revealed a significant difference in
distribution of the RGD-targeted nanoemulsions in the fast growing
and highly vascularized human colorectal LS174T model compared
to the EW7 model, characterized by slow growth (50% of LS174T),
highly elevated vascular mimicry in the tumor rim [32], and lower
MVD [31]. In the case of the EW7 model with a lower angiogenesis
level and vascular mimicry, the majority of the RGD nanoparticle
uptake occurred nonspecifically and might explain the relatively homo-
geneous nanoparticle distribution pattern, which was similar to the
LS174T control group injected with the untargeted nanoparticles. In
this way, the EW7 RGD group served as a control for both, i.e., the
targeted as well as untargeted LS174T groups. On the contrary, in the
LS174T RGD nanoparticle tumors, the high expression of the αvβ3
integrin, predominantly observed at the periphery of the tumor, caused
a shift away from the homogenous accumulation pattern toward a pat-
tern corresponding prevalently to documented expression of the integ-
rin [36]. Because αvβ3 integrin expressed at endothelial cells is directly
accessible from the circulation, targeting of RGD-functionalized nano-
particles is faster than the passive accumulation owing to the EPR
effect. Therefore, the first one of these two competing processes dom-
inates the second in the case of a high receptor expression at the tumor
vasculature [37,38].
Whereas MRI served to show the accumulation pattern within the
tumors 4 hours after injection, NIRF imaging provided time-resolvedA–C) of one representative mouse from each group, 24 hours after
ch organ or tumor were normalized to the sum total of all organs
hin a group (LS174T RGD: n= 6mice, LS174T control: n= 3mice,
Figure 7. Ex vivo Perls staining for iron oxide showed accumulation of the nanoparticles in the tumor vessel endothelium (A–C) com-
pared to the rather homogenous distribution within the tumor tissue in the control (D). CLSM corroborated these results, where the red
fluorescence (rhodamine B) of RGD-conjugated nanoparticles could be co-localized with the fluorescently labeled vessel marker iso-
lectin GS-IB4 (E–H), contrary to the unconjugated control particles (I–L).
Neoplasia Vol. 14, No. 10, 2012 Nanoemulsions for Tumor Angiogenesis Phenotyping Jarzyna et al. 971information about the fate of the particles on the whole tumor level for
a period of 24 hours. The statistically significant difference in accumu-
lation kinetics between the three investigated groups for the time points
up to 6 hours was given as follows: LS174T RGD > LS174T control >
EW7 RGD.
Histologic examination served to corroborate the accumulation of
nanoparticles in the tumor tissue. Perls staining, used to visualizeFigure 8. Histologic CD31 staining was performed for EW7 and LS17
section was captured with an automated bright-field microscope (20×
to one. (A) An example of a high-resolution image of a stitched CD3
color-selected to generate a black and white image with just the visib
The three insets show the vessel staining in the original magnification
was a statistically significant difference (P < .05) in CD31 signal b
LS174T: n = 5 tumors; mean values ± SD).iron oxide deposits in tissue, demonstrated the co-localization of
the targeted particles with the vessel walls, whereas untargeted nano-
emulsions were found extravasated and diffusely spread throughout
the tissue. CLSM of rhodamine B–labeled nanoparticles corroborated
the Perls staining results. The biodistribution, assessed by measuring the
Cy7 fluorescence counts of the whole organs and the tumors after
excision, revealed a high-dose percentage of the targeted contrast agent4T tumors to determine the microvessel density. One entire tumor
objective) generating multiple images that were stitched together
1-stained EW7 tumor section. The red bright-field CD31 stain was
le CD31 signal (B) and the area fraction in percent was determined.
(A) with the corresponding black and white equivalents (B). There
etween the two chosen tumor models (C) (EW7: n = 4 tumors;
972 Nanoemulsions for Tumor Angiogenesis Phenotyping Jarzyna et al. Neoplasia Vol. 14, No. 10, 2012in the LS174T tumors (normalized to the liver: 35%), a highly desir-
able property of a contrast agent.
The MVD of the two used tumor models was assessed using CD31
staining and revealed LS174T tumors to have a much higher angio-
genesis level than the EW7 counterpart. It is important to stress that
such an assessment of MVD alone does not provide information about
the proliferating fraction of endothelial cells within a tumor at a given
time point. However, inmostmousemodels—unlike human tumors—
high MVD is associated to intense ongoing angiogenesis [39]. Usually,
the degree of MVD increases with tumor types that have higher rates
of nutrient or oxygen consumption compared to others with a lower
level metabolic requirement. Whereas MVD has often been shown
to be a prognostic indicator in many tumor studies, its measurement
for monitoring of antiangiogenic therapy has not been demonstrated
to be reliable. A decrease in MVD following antiangiogenic therapy
is certainly a confirmation of its efficacy, but an unchanged MVD is
not necessarily a proof for its inefficacy [10]. In cases of equal tumor cell
and endothelial cell dropout, no changes inMVD are detectable, as, e.g.,
shown in a case of multiple myeloma treatment with thalidomide, where
not all tumor regressions were associated with an MVD decrease [40].
In light of this, because our nanoparticles were shown to be able to
distinguish between different levels of angiogenesis in two distinct
tumor models by directly targeting the αvβ3 receptor as visualized
by NIRF and MRI, it is imaginable that they could be not only used
as a noninvasive contrast agent for angiogenic phenotyping but also
to reliably monitor response to antiangiogenic therapy, like we have
shown with paramagnetic liposomes [41]. The efficacy of the latter
then would be expressed as a change in nanoparticle kinetics moni-
tored by NIRF imaging and/or differences in T2* signal loss pattern
using MRI after injection over time. Moreover, we found in a very
recent parallel study that our nanoparticle platform could be modi-
fied by implementation of cholesterol to form a stable nanocarrier
with a PEG content that could be judiciously varied in a range of
5 to 50 mol%. Lower PEG contents proved to even highly increase
its targeting capabilities to the αvβ3 receptors of newly forming vessels
[37]. An improved modification of our nanoemulsion of this sort
might result in a much higher sensitivity for detecting changes in
neoangiogenesis during the course of treatment. Furthermore, by
using this modified version of our nanoemulsion formulation, it
could be convincingly shown that RGD-targeted nanoparticles began
to accumulate as early as 10 to 30 minutes after i.v. injection and
gave a clear binding pattern 2 hours after administration. In contrast,
untargeted control particles showed almost no accumulation within
the first 30 minutes and a very heterogeneous pattern after 2 to 4 hours.
Only 8 hours after injection, all the particles extravasated into the tumor
tissue. These data corroborate our finding that RGD-targeted nano-
particles show a higher accumulation compared to the untargeted con-
trol within the first hours after i.v. administration, as presented in the
24-hour kinetics herein. Another recent study using RGD-targeted,
superparamagnetic polymeric micelle nanoprobes, combined with
T2*-weighted time-resolved MRI, demonstrated an increased accu-
mulation of the probe over the control in subcutaneous tumor animal
models during the first 30 minutes after i.v. injection, showing an onset
already within the first 5 minutes [38].
In a recently published study with a smaller, 50-nm version of the
RGD nanoemulsion presented here, which also had hydrophobic gluco-
corticoids incorporated, we achieved significant tumor growth inhibi-
tion, demonstrating the versatility of this nanocarrier and its use for
theranostics [42].In conclusion, the RGD-conjugated nanoparticle contrast agent
presented in this study can be used to noninvasively investigate dif-
ferences in angiogenic activity in tumors and for angiogenesis pheno-
typing of tumors. Its biodegradability, flexibility, and capability of
encapsulating hydrophobic materials/drugs make this platform suitable
for theranostics and the tailored antiangiogenesis combination therapy
with highly potent but water-insoluble cytotoxic agents.Acknowledgments
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